Publications and Innovation

Dec. 1, 2021, The newly published article presents the performance of the IBP4/SHBG biomarker pair in predicting spontaneous preterm birth (sPTB) in low and middle income geographies, with prespecified adjustment for demographic differences between the populations.

November 3, 2021, Sera Prognostics announced the publication of a rigorous  validation of a clinical decision point at spontaneous preterm birth (sPTB) risk of 15%, as determined by the company’s PreTRM® test.

September 14, 2021- Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs.

August 17, 2021- Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare

May 20, 2020 - Sera Prognostics, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine.

January 2020 – Abstract of data to determine the performance of a previously validated, clinically available, proteomic preterm birth (PTB) predictor in an independent cohort distinct from the tone in which it was developed, that will be presented at the Society for Maternal-Fetal Medicine’s 2020 Annual Meeting.

Quote icon
“Through a systematic & rigorous approach to biomarker discovery we characterize the proteome of pregnancy. These significant discoveries pave the way toward a paradigm shift in obstetrical care in pregnancy and open the door to the identification of women at risk for aberrant conditions of pregnancy, such as preterm birth”.

Jay Boniface, PhD

Chief Scientific Officer

Jay Boniface, PhD, Chief Scientific Officer
Scroll to Top